RT Journal Article
SR Electronic
T1 A meta-analysis on Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China.
JF Saudi Medical Journal
JO Saudi Med J
FD Prince Sultan Military Medical City
SP 675
OP 678
VO 32
IS 7
A1 Hou, Siyuan
A1 Yang, Wei
YR 2011
UL http://smj.org.sa/content/32/7/675.abstract
AB OBJECTIVES: To evaluate the curative effect of Rituximab combined CHOP chemotherapy in patients with non-Hodgkin lymphoma in China.METHODS: We conducted this study in the Affiliated Shengjing Hospital of China Medical University, Shenyang, China between June and December 2010. We used the systematic review method of The Cochrane Collaboration to collect randomized controlled trials (RCTs) of Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma by computer databases during the period 2004-2009.RESULTS: Seven trials involving 357 patients were retrieved. The complete remission rate of Rituximab combined CHOP chemotherapy was higher than that of CHOP chemotherapy alone (odds ratio = 3.02, 95% confidence interval: 1.94-4.72, p<0.00001).CONCLUSIONS: Non-Hodgkin lymphoma treated by Rituximab combined CHOP chemotherapy can produce a positive therapeutic effect in China.